Startups Directory

Monitoring Life is a digital health startup developing intelligent medical devices for remote cardiac monitoring. Our flagship solution, Sensocor ML, is a portable multisensor that enables early detection and continuous home monitoring of heart failure patients, improving quality of life while reducing the burden on healthcare systems.

Sensocor ML addresses the lack of continuous, objective, and early detection tools for heart failure deterioration in home settings. Current heart failure management relies heavily on sporadic hospital visits, patient self-reporting, and late clinical symptoms, which often lead to delayed interventions, avoidable hospitalizations, and increased healthcare costs. Our technology enables continuous, non-invasive, at-home cardiac monitoring, allowing clinicians to detect early physiological changes, intervene sooner, and improve patient outcomes while reducing system burden.

Our technology positively impacts society by enabling people with chronic heart failure to monitor their health safely from home, improving quality of life and independence. By detecting early signs of deterioration, it helps prevent avoidable hospitalizations and reduces mortality risk. At the same time, it alleviates pressure on healthcare systems, optimizes clinical resources, and lowers long-term costs, contributing to more sustainable, accessible, and equitable care for aging populations.

2M€

2M€

: Bioactive Surfaces belongs to a group of four companies with headquarters in the Scientific Park of Madrid, Spain. Our companies pioneer advanced biotechnology, biomaterials, and functionalization technologies, cellular and molecular therapies, tissue engineering, and regenerative medicine. Our products include molecular therapies for ischemic stroke and age-related macular degeneration (both of them entering clinical trials), retina-on-chip platforms for drug screening, adaptive drug delivery systems, biofunctionalized prostheses, spider-like 3D tissue bioprinters, and precision AFM tips. We are fast, highly competent and efficient, capable of delivering cutting-edge solutions under tight timelines. With extensive experience in EU projects (e.g., at the present we coordinate the Pathfinder ISOS & THOR projects).

Infections, inflammations, failures and delayed healing related to medical prostheses and medical devices/sensors implanted in the human body. Bioactive Surfaces’ rThAB™ (Thermally Activated Biofunctionalization) technology, enables controlled biofunctionalization of the surface of any material, with a radical improvement of the biological interactions and performance of the prostheses. The implant of any type of prostheses/devices in the human body suffer from (1) bacterial/fungal infections, since biofilm formation on prosthetic surfaces can lead to peri-implantitis, mucositis, and chronic infections, especially common in dental implants due to the oral microbiome (2) poor osseointegration, i.e., inadequate bonding between the implant and surrounding bone leads to prosthesis failure, often due to poor surface compatibility or inflammation (iii) immune rejection and inflammation, due to host tissue recognition of the implant as foreign, triggering chronic inflammation or fibrosis (iv) mechanical failure and loosening, caused by micromovements, material fatigue, or lack of biological fixation and (v) delayed healing, particularly in compromised patients, e.g., diabetics, healing around implants can be slow, risking exposure or infection. Conventional surface treatments do not provide precise control over bioactive interfaces, leading to signal instability, foreign body responses, and reduced device performance.

By enabling better-integrated implantable devices and prostheses, Bioactive Surfaces will help to achieve safer and more effective medical technologies. rThAB™-based biofunctionalization will allow advanced implant performance, and long-term device reliability, ultimately leading to better patient outcomes, reduced complications, and accelerated innovation in medical devices and regenerative technologies.

2.0 million EUROs On February 2026 we will start implanting rThAB™-biofunctionalized prostheses in human patients in a public Hospital in Spain. This money will be employed to accelerate the introduction of our technology in the clinic.

5.0 million EUROs

Omnia Mater belongs to a group of four companies with headquarters in the Scientific Park of Madrid, Spain. Our companies pioneer advanced biotechnology, biomaterials, and functionalization technologies, cellular and molecular therapies, tissue engineering, and regenerative medicine. Our products include molecular therapies for ischemic stroke and age-related macular degeneration (both of them entering clinical trials), retina-on-chip platforms for drug screening, adaptive drug delivery systems, biofunctionalized prostheses, spider-like 3D tissue bioprinters, and precision AFM tips. We are fast, highly competent and efficient, capable of delivering cutting-edge solutions under tight timelines. With extensive experience in EU projects (e.g., at the present we coordinate the Pathfinder ISOS & THOR projects).

Endow any biology-, biotechnology-, pharma-, etc. lab with a high-tech, high-performance and affordable 3D tissue bioprinter. Current bioprinting technologies often lack precision, flexibility, and accessibility required to fabricate complex, biologically relevant human tissues. Most systems are expensive, difficult to operate, or limited to narrow applications, slowing adoption in research, pharma, and regenerative medicine. Omnia Mater addresses these limitations through the THOR-X Bioprinter, outcome of a European EIC Pathfinder project led by our companies.

By making high-precision bioprinting more accessible, the company supports innovation in regenerative medicine, drug discovery, and personalized healthcare. Omnia Mater’s technologies accelerate the development of artificial tissues and advanced biological models, reducing reliance on animal testing and improving the predictability of biomedical research.

0.8 million EUROs Initial investment aimed at industrializing the THOR-X Bioprinter.

2.5 million EUROs

Silk Biomed belongs to a group of four companies with headquarters in the Scientific Park of Madrid, Spain. Our companies pioneer advanced biotechnology, biomaterials, and functionalization technologies, cellular and molecular therapies, tissue engineering, and regenerative medicine. Our products include molecular therapies for ischemic stroke and age-related macular degeneration (both of them entering clinical trials), retina-on-chip platforms for drug screening, adaptive drug delivery systems, biofunctionalized prostheses, spider-like 3D tissue bioprinters, and precision AFM tips. We are fast, highly competent and efficient, capable of delivering cutting-edge solutions under tight timelines. With extensive experience in EU projects (e.g., at the present we coordinate the Pathfinder ISOS & THOR projects).

Therapy of ischemic stroke and of Age-related Macular degeneration (AMD). SILK Biomed addresses these challenges through two advanced therapies which employ mesenchymal stem cells’ secretome integrated in silk fibroin hydrogels.

Affecting over 270 million people combined, ischemic stroke and AMD impose a staggering global economic burden exceeding $900 billion annually through lost productivity and high clinical costs. Current therapeutic options remain critically inadequate, as the extremely narrow emergency window for stroke and the repetitive, invasive nature of chronic AMD injections fail to prevent irreversible disability and blindness for the majority of patients. Social Impact: Ischemic stroke is the 3rd leading cause of combined death and disability globally, accounting for over 160 million disability-adjusted life years (DALYs) lost. AMD is responsible for approximately 8.7% of global blindness and is the leading cause of irreversible vision loss in individuals over age 60 in high-income countries.

Contact the company

Contact the company

We develop low-cost advanced carbon nanomaterials for electrochemical applications in batteries and supercapacitors, using waste from the agri-food industry.

The first problem the company solves is that of critical raw materials for the EU (CRMA). These nanomaterials also have their main application in electrochemical energy storage applications such as batteries and supercapacitors. Furthermore, the technology developed allows the use of waste from the agri-food industry, giving it a second life.

This project valorizes agri-food residues into advanced carbonaceous materials including ultra-high surface area activated carbons, tailored mesoporous carbons, and carbon dots - fully aligned with EU sustainability policies. It supports the Waste Framework Directive and the EU Circular Economy Action Plan by transforming residues into secondary raw materials. By reducing reliance on imported graphite and carbons, it reinforces EU strategic autonomy under the Critical Raw Materials Act. The project fosters Rural Development by sustainably valorizing biomass, creating local jobs in collection, conditioning, and logistics. It promotes Upskilling in Green and Circular Technologies, in line with CAP and ESF+. It helps retain population, diversify incomes, and strengthen territorial cohesion, ensuring an inclusive Green Transition.

375.000€

750.000€

Advanced Quantum Propulsion - The first improvement on electric motor principles since that discovery in the 1800s.

Access to the solar system and hundreds of trillions of dollars in new resources

We haven't had a new engine technology since the jet turbine in 1940s.

€3.000.000

€3.000.000

At Umibots we develop autonomous and electric robotics for urban and beach cleaning.

We improved sustainability and reduced the costs of urban and beach cleaning services

It will improve cleanliness and quality of life in cities, reducing the waste collection taxes paid by citizens.

750,000 USD

750,000 USD

Green hydrogen is key to the energy transition, but its high flammability demands reliable, fast, and efficient detection systems. H2-DETECTOR is a startup born in the Department of Applied Physics at the Autonomous University of Madrid, the result of more than 10 years of collaborative research on hydrogen and two-dimensional materials. Our technology is based on next-generation sensors made with dichalcogenides and functionalized graphene, capable of detecting hydrogen quickly, selectively, and with high sensitivity, overcoming the limitations of conventional sensors. The devices operate over a wide temperature range of 0 to 200 °C, with low power consumption, humidity resistance, reduced cost, and potential for industrial scaling, contributing to a safer and more sustainable hydrogen deployment.

Green hydrogen is a key element in the energy transition; however, its high flammability requires reliable, fast, and efficient detection systems. Our technology is based on next-generation sensors fabricated using dichalcogenides and functionalized graphene, capable of detecting hydrogen rapidly, selectively, and with high sensitivity, overcoming the limitations of conventional sensors. The devices operate over a wide temperature range from 0 to 200 °C, with low power consumption, humidity resistance, low cost, and strong potential for industrial scalability, contributing to a safer and more sustainable deployment of hydrogen.

Our technology will have a positive impact on society by improving safety in the growing hydrogen economy, enabling early and reliable detection of hydrogen leaks in industrial, energy, and transport environments. By reducing the risk of accidents, it helps protect people, infrastructure, and the environment. In addition, the sensor supports the safe deployment of green hydrogen, a key pillar of the energy transition toward low-carbon and sustainable energy systems. Its low power consumption, robustness, and scalability make it suitable for widespread use, contributing to safer industrial processes and fostering public trust in hydrogen-based technologies.

628.000 €

500.000 €

Concrete 3D Printing

Parametric construction in concrete in a matter of minutes

Less polution and impact in air quality, using recycled material.

2.000.000 €

0.5 €

Eversens is a MedTech company specialized in the development of advanced diagnostic solutions for respiratory diseases based on exhaled biomarker analysis. Its flagship technology enables precise measurement of FeNO and other respiratory biomarkers to support diagnosis, treatment selection, and disease monitoring in asthma and related conditions. Eversens combines proprietary sensing technology, clinical validation, and a scalable business model to serve both specialised care and emerging home-monitoring applications, with a growing international footprint.

Our technology addresses a critical gap in respiratory care: airway inflammation—the main driver of attacks—cannot currently be monitored continuously or objectively. By enabling real-time, non-invasive measurement of exhaled biomarkers such as FeNO, our solution allows clinicians and patients to track airway inflammation over time, supporting earlier intervention, more precise treatment decisions, improved adherence, and better prevention of exacerbations in both clinical and home-care settings.

evernoa® mini has the potential to deliver a significant positive impact on patients, healthcare systems, and society as a whole. By enabling continuous, objective monitoring of airway inflammation—currently not possible outside clinical visits—it supports earlier intervention, better disease control, and the prevention of severe exacerbations in asthma and other chronic inflammatory airway diseases. Health-economic modelling, conducted in line with HM Treasury’s Green Book Methodology and European payer perspectives, demonstrates that the use of evernoa® mini can reduce healthcare costs by approximately €440 per patient per year driven by fewer attacks, lower disease severity, reduced hospitalisations, emergency visits, and more efficient medication use. In parallel, patients experience a measurable health benefit, with an estimated gain of 0.05 QALYs per patient-year, reflecting improved symptom control and quality of life. At scale, these improvements translate into substantial system-level benefits. The widespread adoption of evernoa® mini across Europe could prevent hundreds of thousands of severe exacerbations annually, significantly reduce unscheduled healthcare utilisation, and generate multi-billion-euro savings through avoided hospitalisations, emergency care, and optimised use of high-cost therapies such as biologics. Importantly, the technology also improves the identification of non-responders and non-adherent patients, enabling more appropriate and cost-effective treatment decisions. Beyond healthcare outcomes, evernoa® mini contributes to broader societal goals. By reducing avoidable healthcare visits, it lowers patient travel and associated emissions, supporting Europe’s environmental and sustainability objectives. Improved disease control also leads to fewer missed work and school days, increasing productivity, educational continuity, and overall social well-being. In summary, evernoa® mini delivers a rare combination of clinical benefit, economic efficiency, patient empowerment, and environmental impact aligning closely with European priorities for healthier populations, more resilient healthcare systems, and a more sustainable future.

€4 millions

€3 Millions

We aim to develop, manufacture, and market a next-generation biomaterial derived from bacterial cellulose, designed to serve as a sustainable and innovative alternative to animal leather.

Our product, NGL, addresses the significant sustainability challenges posed by the leather industry, which affects multiple sectors, including fashion and automotive. NGL will also serve as a reliable leather alternative as supply chain disruptions will become more pronounced. Notably, various studies predict a drastic reduction in the meat cow supply by 2030 - an event that will directly affect leather availability, since leather is a byproduct of the meat industry.

NGL will have a positive impact on society by significantly reducing the environmental footprint of the leather industry. Because our product is biodegradable and animal-free, it eliminates the need for livestock farming, which in turn conserves land and water resources. Additionally, the manufacturing process for NGL requires minimal chemical use—especially in tanning—further decreasing pollution and health risks. By providing a sustainable, non-animal alternative, NGL supports ethical consumption and environmental stewardship.

€500.000

€2,5M

CAPTOPLASTIC is an innovative technology company specialized in developing advanced solutions for the control and removal of microplastics from water. Our mission is to contribute to improve environmental quality and to support early compliance with the requirements established in the latest EU Directives on this matter. Since its foundation on 2020, CAPTOPLASTIC is recognized as a knowledge‑based company with a strong intellectual property portfolio, which is protected by several patents that ensure the exclusivity and robustness of our technological solutions. Our activity is structured around two main lines: - Microplastic control, through a validated, reproducible, and standardized quantification method applicable to different water matrices, like the influent, effluent, and sludge at WWTP's. - Early microplastic capture, by means of high‑efficiency retention solutions designed to operate at strategic points within the water treatment process, reducing the transfer of microplastics to the biological stage, the final effluent, and the sludge. Our technologies are designed not only to achieve high performance in microplastic detection and capture, but also to promote resource reuse and zero‑waste operational principles, reflecting our strong commitment to environmental sustainability and protection.

Control and removal of microplastics from water matrices

CAPTOPLASTIC’s technology will have a significant positive impact on society by enabling faster and more accurate monitoring of microplastic concentrations across different types of water. It will also facilitate the removal of microplastics directly within WWTP's, preventing their discharge into natural water bodies and drastically reducing their presence in the sludge generated at this facilities. As a result, this sludge can be used more safely when applied in agricultural settings.

€7M

€7M

Deep tech company

Early detection and localization of arrhythmias without surgical intervention

Cost and time savings in hospitals

N/A

N/A

tranSkriptorium is an AI-driven spin-off from the Universitat Politècnica de València (PRHLT research center) focused on unlocking non-digitally-native documents. We have developed a proprietary technology, Probabilistic Indexing (PrIx), that goes beyond traditional OCR and HTR, enabling direct search, structuring, and metadata extraction directly from document images—regardless of language, handwriting style, layout, or preservation condition. Our solution allows archives, libraries, and institutions to locate information, identify entities, detect relationships, and generate structured databases at scale, while supporting (not replacing) expert human work. PrIx significantly reduces processing time and costs, transforming inaccessible historical and administrative collections into searchable, reusable knowledge for research, governance, and cultural heritage preservation.

tranSkriptorium addresses one of the most persistent and costly challenges faced by archives, institutions, and organizations worldwide: the inaccessibility of non-digitally-native documents. Vast amounts of handwritten, degraded, multilingual, or irregularly structured material remain effectively invisible because traditional technologies such as OCR and even advanced HTR fail under real archival conditions. Current workflows rely heavily on manual reading, transcription, and cataloguing, which are slow, expensive, and impossible to scale with existing human resources. As a result, valuable information cannot be searched, linked, or reused, limiting institutional efficiency, research potential, and public access. Our technology, Probabilistic Indexing (PrIx), solves this by enabling direct search and information extraction directly on document images, without requiring full transcription or ideal document quality. It transforms previously inaccessible collections into structured, searchable data, reducing processing costs and time while preserving expert oversight and decision-making.

tranSkriptorium has a direct and measurable societal impact by democratizing access to information that has remained inaccessible for decades or centuries. By unlocking non-digitally-native documents, our technology enables public institutions, researchers, journalists, and citizens to access historical, legal, and administrative records that shape collective memory, rights, and governance. PrIx reduces the dependency on slow, manual processes, allowing institutions to operate more efficiently with limited resources while preserving expert control and interpretative authority. This supports transparency, accountability, and evidence-based decision-making in both public administration and cultural heritage management. Beyond access, our technology promotes inclusion: it works across languages, scripts, and document conditions, preventing the marginalization of smaller archives or underfunded institutions. Ultimately, tranSkriptorium contributes to preserving cultural heritage, accelerating research, and ensuring that knowledge embedded in historical and administrative records becomes usable, searchable, and meaningful for society at large.

tranSkriptorium is seeking a €1.5M investment round focused explicitly on commercial scaling and technological consolidation. €650k – Technological Development and €850k – Business Development

1.500.000 €

Spanish-based scale-up, originating as a spin-off from the CSIC. ADP specializes in the design, development and manufacturing of advanced mineral filters for cosmetic applications. The company is currently the only supplier combining UV filters with color, or UV filters with active ingredients, within a single product, enabling protection, prevention and color across sun care, skin care and make-up applications. ADP’s technology platform is built on a proprietary and patented process, Co-Smart, a one-of-a-kind, waterless manufacturing technology that does not require chemical additives, does not generate waste, and operates with low energy consumption. This process is a key enabler of the unique functional and performance characteristics of ADP’s products.

The cosmetic industry is under increasing regulatory and environmental pressure due to the limitations of conventional chemical UV filters, which raise health concerns and present significant environmental risks. ADP addresses this challenge through a patented, proprietary dry-dispersion manufacturing technology that enables the production of high-efficiency, nano-free mineral UV filters with superior performance and transparency on skin. Unlike traditional mineral filters, ADP’s technology delivers perfectly balanced particle size, broad-spectrum protection (UV, visible light and IR-A), and full regulatory approval (USP–FDA, ECOCERT, COSMOS, NATRUE). ADP is the only supplier capable of integrating UV protection, color and functional actives into a single ingredient, significantly reducing formulation complexity and costs while expanding applications across sun care, skin care and make-up. The result is a scalable, defensible technology platform aligned with current and future regulatory, sustainability and market requirements.

ADP’s technology enables a safer, more effective and sustainable approach to sun protection and daily skin care. Through a patented manufacturing process, ADP develops nano-free mineral UV filters with perfectly balanced particle size (>100 nm), designed to deliver high skin tolerance and efficacy, making them especially suitable for sensitive and reactive skin. ADP is the only supplier combining UV protection and color in a single ingredient, providing true broad-spectrum protection against UVB, UVA, blue light, visible light and infrared-A radiation. This simplifies formulations, improves performance, and supports more consistent daily photoprotection across multiple cosmetic applications. In parallel, ADP’s ingredients offer a more environmentally responsible alternative to chemical UV filters, which are increasingly linked to marine pollution. ADP’s solutions are coral-friendly and certified by COSMOS, ECOCERT and NATRUE, supporting the cosmetic industry’s transition towards more sustainable products.

We are seeking a strategic investment partner to scale our company and unlock the next phase of growth.

Rather than a traditional financial round, ADP is assessing strategic transactions with industrial partners. Investment size is therefore flexible and linked to the strategic value and integration roadmap